Bispecific Antibodies in the Treatment of Hematologic Malignancies

被引：51

作者：

Duell, Johannes ^{[1
]}

Lammers, Philip E. ^{[2
]}

Djuretic, Ivana ^{[3
]}

Chunyk, Allison G. ^{[4
]}

Alekar, Shilpa ^{[4
]}

Jacobs, Ira ^{[5
]}

Gill, Saar ^{[6
,7
]}

机构：

[1] Univ Klinikum Wurzburg, Dept Internal Med 2, Wurzburg, Germany

[2] Baptist Canc Ctr, Memphis, TN USA

[3] Pfizer Inc, San Francisco, CA USA

[4] Pfizer Inc, La Jolla, CA USA

[5] Pfizer Inc, New York, NY 10017 USA

[6] Univ Penn, Blood & Marrow Transplantat Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[7] Univ Penn, Div Hematol & Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 106卷 / 04期

关键词：

ACUTE LYMPHOBLASTIC-LEUKEMIA; CYTOKINE RELEASE SYNDROME; CAR T-CELLS; CLINICAL DEVELOPMENT; BLINATUMOMAB; THERAPY; RESISTANCE; DEPLETION; EFFICACY; SAFETY;

D O I：

10.1002/cpt.1396

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Monoclonal antibody therapies are an important approach for the treatment of hematologic malignancies, but typically show low single-agent activity. Bispecific antibodies, however, redirect immune cells to the tumor for subsequent lysis, and preclinical and accruing clinical data support single-agent efficacy of these agents in hematologic malignancies, presaging an exciting era in the development of novel bispecific formats. This review discusses recent developments in this area, highlighting the challenges in delivering effective immunotherapies for patients.

引用

页码：781 / 791

页数：11

共 50 条

[41] Bispecific Antibodies in the Treatment of Multiple Myeloma
Zhou, Xiang
Xiao, Xianghui
Kortuem, Klaus Martin
Einsele, Hermann
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (02) : 361 - 381
[42] Bispecific Antibodies for the Treatment of Multiple Myeloma
Goldsmith, Scott R.
Streeter, Shawn
Covut, Fahrettin
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2022, 17 (06) : 286 - 297
[43] Bispecific Antibodies for Lymphoid Malignancy Treatment
Bisio, Matteo
Legato, Luca
Fasano, Filippo
Savelli, Corrado Benevolo
Boccomini, Carola
Nicolosi, Maura
Santambrogio, Elisa
Freilone, Roberto
Novo, Mattia
Botto, Barbara
CANCERS, 2025, 17 (01)
[44] Bispecific antibodies in the treatment of multiple myeloma
Devasia, Anup Joseph
Chari, Ajai
Lancman, Guido
BLOOD CANCER JOURNAL, 2024, 14 (01):
[45] The potential of bispecific antibodies for treatment of hemophilia A
Shima, M.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 5 - 6
[46] Therapeutic monoclonal antibodies in hematologic malignancies: Biological responses and safety
Rate, R.
Ludwig, W. -D.
ANNALS OF HEMATOLOGY, 2006, 85 : 42 - 46
[47] Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignancies
Rafei, Hind
Rezvani, Katayoun
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 764 - 766
[48] Treatment of invasive aspergillosis in children with hematologic malignancies
Walid Abuhammour
Rashed A. Hasan
The Indian Journal of Pediatrics, 2004, 71 (9) : 837 - 843
[49] Targeting of Ubiquitin Ligases for the Treatment of Hematologic Malignancies
Ebert, B. Levine
ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 27 - 27
[50] ALPHA-INTERFERON IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
ROTH, MS
FOON, KA
AMERICAN JOURNAL OF MEDICINE, 1986, 81 (05): : 871 - 882

← 1 2 3 4 5 →